Clinical use of cerebrospinal fluid biomarkers in Alzheimers disease

Biomarkers in Medicine

Volumn 6, Issue 4, 2012, Pages 371-376

  Zetterberg, Henrik ^a,b   Lunn, Michael P ^b,c   Herukka, Sanna Kaisa ^d,e  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^d UNIVERSITY OF EASTERN FINLAND   (Finland)

^e KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Alzheimers disease; amyloid; biomarkers; blood brain barrier; cerebrospinal fluid; inflammation; tau

Indexed keywords

ALBUMIN; AMYLOID; AMYLOID BETA PROTEIN[1-42]; BIOLOGICAL MARKER; NEUROFILAMENT LIGHT PROTEIN; NEUROFILAMENT PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID FLOW; CLINICAL ASSESSMENT; COGNITIVE DEFECT; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; HUMAN; MEMORY DISORDER; MILD COGNITIVE IMPAIRMENT; NERVE FIBER DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROCHEMISTRY; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUALITY CONTROL; SENSITIVITY AND SPECIFICITY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; BRAIN; HUMANS; PEPTIDE FRAGMENTS; TAU PROTEINS;

EID: 84865528839     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.12.47     Document Type: Article

References (58)

1. Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 368, 387-403 (2006). (Pubitemid 44108123)
2. Andreasen N, Minthon L, Davidsson P et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 58, 373-379 (2001). (Pubitemid 32217453)
3. Blennow K, Wallin A, Hager O. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol. Scand. 88, 221-223 (1993). (Pubitemid 23288659)
4. Peskind ER, Riekse R, Quinn JF et al. Safety and acceptability of the research lumbar puncture. Alzheimer Dis. Assoc. Disord. 19, 220-225 (2005). (Pubitemid 44366623)
5. Zetterberg H, Tullhog K, Hansson O, Minthon L, Londos E, Blennow K. Low incidence of post-lumbar puncture headache in 1, 089 consecutive memory clinic patients. Eur. Neurol. 63, 326-330 (2010).
6. Strozyk D, Blennow K, White LR, Launer LJ. CSF Abeta 42 levels correlate with amyloidneuropathology in a population-based autopsy study. Neurology 60, 652-656 (2003). (Pubitemid 36246085)
7. Fagan AM, Mintun MA, Mach RH et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 59, 512-519 (2006). (Pubitemid 43358072)
8. Forsberg A, Engler H, Almkvist O et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 29, 1456-1465 (2008).
9. Grimmer T, Riemenschneider M, Forstl H et al. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid. Biol. Psychiatry 65, 927-934 (2009).
10. Tapiola T, Alafuzoff I, Herukka SK et al. Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 66, 382-389 (2009). The best paper establishing the association of cerebrospinal fluid (CSF) biomarkers with Alzheimer's pathology.
11. Fagan AM, Head D, Shah AR et al. Decreased cerebrospinal fluid Abeta (42) correlates with brain atrophy in cognitively normal elderly. Ann. Neurol. 65, 176-183 (2009). One among five important studies showing preclinical changes in CSF levels of amyloid-b (Ab) 1-42.
12. Gustafson DR, Skoog I, Rosengren L, Zetterberg H, Blennow K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. J. Neurol. Neurosurg. Psychiatry 78, 461-464 (2007). One among five important studies showing preclinical changes in CSF levels of Ab1-42. (Pubitemid 46662891)
13. Stomrud E, Hansson O, Blennow K, Minthon L, Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement. Geriatr. Cogn. Disord. 24, 118-124 (2007). One among five important studies showing preclinical changes in CSF levels of Ab1-42. (Pubitemid 47094071)
14. Ringman JM, Coppola G, Elashoff D et al. Cerebrospinal fluid biomarkers and proximity to diagnosis in preclinical familial Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 33, 1-5 (2012). One among four important studies showing preclinical changes in CSF levels of Ab1-42.
15. Ringman JM, Younkin SG, Pratico D et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 71, 85-92 (2008). One among four important studies showing preclinical changes in CSF levels of Ab1-42.
16. Otto M, Esselmann H, Schulz-Shaeffer W et al. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 54, 1099-1102 (2000). (Pubitemid 30151852)
17. Gisslen M, Krut J, Andreasson U et al. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol. 9, 63 (2009).
18. Mattsson N, Axelsson M, Haghighi S et al. Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis. Mult. Scler. 15, 448-454 (2009).
19. Mattsson N, Bremell D, Anckarsater R et al. Neuroinflammation in Lyme neuroborreliosis affects amyloid metabolism. BMC Neurol. 10, 51 (2010).
20. Trojanowski JQ, Schuck T, Schmidt ML, Lee VM. Distribution of tau proteins in the normal human central and peripheral nervous system. J. Histochem. Cytochem. 37, 209-215 (1989). (Pubitemid 19039170)
21. Lovestone S, Reynolds CH. The phosphorylation of tau: a critical stage in neurodevelopment and neurodegenerative processes. Neuroscience 78, 309-324 (1997). (Pubitemid 27170324)
22. Mattsson N, Savman K, Osterlundh G, Blennow K, Zetterberg H. Converging molecular pathways in human neural development and degeneration. Neurosci. Res. 66, 330-332 (2009).
23. Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 8, 663-672 (2007). (Pubitemid 47283144)
24. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. Exp. Gerontol. 45, 30-40 (2010).
25. Buerger K, Teipel SJ, Zinkowski R et al. CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59, 627-629 (2002). (Pubitemid 34920005)
26. Buerger K, Ewers M, Pirttila T et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129, 3035-3041 (2006). (Pubitemid 44684523)
27. Bian H, Van Swieten JC, Leight S et al. CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70, 1827-1835 (2008). (Pubitemid 351653951)
28. Grossman M, Farmer J, Leight S et al. Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann. Neurol. 57, 721-729 (2005). (Pubitemid 40628861)
29. Blennow K, Johansson A, Zetterberg H. Diagnostic value of 14-13-3beta immunoblot and T-tau/P-tau ratio in clinically suspected Creutzfeldt-Jakob disease. Int. J. Mol. Med. 16, 1147-1149 (2005).
30. Riemenschneider M, Wagenpfeil S, Vanderstichele H et al. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol. Psychiatry 8, 343-347 (2003). (Pubitemid 36712928)
31. Otto M, Wiltfang J, Cepek L et al. Tau protein and 14-13-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58, 192-197 (2002). (Pubitemid 34084207)
32. Otto M, Wiltfang J, Tumani H et al. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci. Lett. 225, 210-212 (1997). (Pubitemid 27191632)
33. Hesse C, Rosengren L, Andreasen N et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci. Lett. 297, 187-190 (2001). (Pubitemid 32011305)
34. Ost M, Nylen K, Csajbok L et al. Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury. Neurology 67, 1600-1604 (2006). (Pubitemid 44747930)
35. Zetterberg H, Hietala MA, Jonsson M et al. Neurochemical aftermath of amateur boxing. Arch. Neurol. 63, 1277-1280 (2006). (Pubitemid 44379829)
36. Samgard K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E. Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. Int. J. Geriatr. Psychiatry 25, 403-410 (2010).
37. Blom ES, Giedraitis V, Zetterberg H et al. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype. Dement. Geriatr. Cogn. Disord. 27, 458-464 (2009).
38. Buerger K, Ewers M, Andreasen N et al. Phosphorylated tau predicts rate of cognitive decline in MCI subjects: a comparative CSF study. Neurology 65, 1502-1503 (2005). (Pubitemid 41552795)
39. Bostrom F, Hansson O, Blennow K et al. Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies. Dement. Geriatr. Cogn. Disord. 28, 314-319 (2009).
40. Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 74, 1531-1537 (2010).
41. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5, 228-234 (2006). Well-standardized monocenter study that shows excellent predictive power of CSF biomarkers for Alzheimer's disease. (Pubitemid 43238346)
42. Mattsson N, Zetterberg H, Hansson O et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393 (2009). Multicenter study that illustrates important aspects of the need of biomarker standardization.
43. Shaw LM, Vanderstichele H, Knapik-Czajka M et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 65, 403-413 (2009).
44. Visser PJ, Verhey F, Knol DL et al. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 8, 619-627 (2009).
45. Herukka SK, Hallikainen M, Soininen H, Pirttila T. CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 64, 1294-1297 (2005).
46. Rosengren LE, Karlsson JE, Sjogren M, Blennow K, Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology 52, 1090-1093 (1999). (Pubitemid 29161631)
47. Agren-Wilsson A, Lekman A, Sjoberg W et al. CSF biomarkers in the evaluation of idiopathic normal pressure hydrocephalus. Acta Neurol. Scand. 116, 333-339 (2007). (Pubitemid 47537413)
48. Wallin A, Sjogren M. Cerebrospinal f.luid cytoskeleton proteins in patients with subcortical white-matter dementia. Mech. Ageing Dev. 122, 1937-1949 (2001). (Pubitemid 32925104)
49. de Jong D, Jansen RW, Pijnenburg YA et al. CSF neurofilament proteins in the differential diagnosis of dementia. J. Neurol. Neurosurg. Psychiatry 78, 936-938 (2007). (Pubitemid 47310827)
50. Norgren N, Sundstrom P, Svenningsson A, Rosengren L, Stigbrand T, Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 63, 1586-1590 (2004). (Pubitemid 39507573)
51. Gisslen M, Hagberg L, Brew BJ, Cinque P, Price RW, Rosengren L. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J. Infect. Dis. 195, 1774-1778 (2007). (Pubitemid 46870250)
52. Bjerke M, Andreasson U, Rolstad S et al. Subcortical vascular dementia biomarker pattern in mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 28, 348-356 (2009).
53. Blennow K, Wallin A, Fredman P, Karlsson I, Gottfries CG, Svennerholm L. Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol. Scand. 81, 323-326 (1990). (Pubitemid 20174132)
54. Wallin A, Blennow K, Rosengren L. Cerebrospinal fluid markers of pathogenetic processes in vascular dementia, with special reference to the subcortical subtype. Alzheimer Dis. Assoc. Disord. 13, S102-S105 (1999).
55. Tumani H, Nolker G, Reiber H. Relevance of cerebrospinal fluid variables for early diagnosis of neuroborreliosis. Neurology 45, 1663-1670 (1995).
56. Blennow K, Wallin A, Fredman P, Gottfries CG, Karlsson I, Svennerholm L. Intrathecal synthesis of immunoglobulins in patients with Alzheimer's disease. Eur. Neuropsychopharmacol. 1, 79-81 (1990).
57. Mattsson N, Rosen E, Hansson O et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 78, 468-476 (2012).
58. Zetterberg H, Mattsson N, Blennow K. Cerebrospinal fluid analysis should be considered in patients with cognitive problems. Int. J. Alzheimers Dis. 2010, 163065 (2010).